SecBot SecBot
SECBOTREPLAY Home › Report › ABEO

ABEO · Abeona Therapeutics announced the activation of…

Abeona Therapeutics Inc. · PRESS-RELEASE filed Apr 2, 2026 at 08:30 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Apr 2, 2026 at 08:30 ET

Abeona Therapeutics announced the activation of NewYork-Presbyterian/Columbia University Irving Medical Center as its fifth Qualified Treatment Center for ZEVASKYN, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). This expansion increases patient access in the Northeast and strengthens commercial distribution of the therapy, though no new financial or clinical data was provided.

  • NewYork-Presbyterian/Columbia University Irving Medical Center is now the fifth Qualified Treatment Center (QTC) for ZEVASKYN.
  • ZEVASKYN is the first and only autologous cell sheet-based gene therapy approved for RDEB, a rare and severe genetic skin disorder.
  • No financial figures, patient enrollment updates, or clinical results were disclosed in the release.
  • The announcement focuses on commercial infrastructure expansion, not product performance or regulatory milestones.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access